Sigilon Therapeutics Stock Predictions

Healthcare > Biotechnology

Buy SGTX

*Your capital is at risk

$22.47

+0 (+0%)

At Close: Nov 09, 2023

Currently predicting for Thu, 18 Jun 2026

SGTX Live board

Community Bull/Bear

Target Next close

Join the SGTX prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

SGTX Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For SGTX

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

SGTX Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT SIGILON THERAPEUTICS, INC.

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged rel...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
IDYA $28.98	7.87%	Jun 12
DHI $146.71	3.93%	Jun 10
PHM $118.49	2.86%	Jun 10
EAT $140.46	13.06%	Jun 05
TPR $140.47	3.84%	Jun 04

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by